Versant adds $7.5M to upstart biotech's A round

Doyleston, PA-based Novira Therapeutics reports that Versant Ventures, a high-profile biotech venture group, has added $7.5 million to their Series A, which now stands at $25 million. Novira's working theory is that by interfering with capsids--a viral protein involved in replication and transmission--the company can introduce a new treatment for viral diseases. 5AM Ventures and Canaan led the first close of the round. WuXi PharmaTech as well as existing investors BioAdvance, Mid-Atlantic Angel Group, Robin Hood Ventures and Delaware Crossing Investment Group joined the round earlier. The co-founder of the biotech is Osvaldo Flores, who had been director of antiviral research at Merck ($MRK). Release

 

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.